Chain Pharmacy

Pharmacies and pharmacists can help the rapid deployment of COVID-19 vaccines when available, NACDS said. 

In part 2 of our interview, Mike Johnston, founder and chief executive officer of the National Pharmacy Technician Association (NPTA), discussed the results of their recent survey, which found that many pharmacists and pharmacy technicians feel unsafe from COVID-19 at their workplaces.

Mike Johnston, founder and chief executive officer of the National Pharmacy Technician Association (NPTA), joined Drug Topics® to discuss their recent survey that pinpointed where pharmacists are feeling most unprotected during the pandemic.

“The reality is that pharmacy workers are smack dab in the middle of trauma.”

Eleven Schnuck Markets’ pharmacies will close after CVS Pharmacy’s acquisition of 110 Schnuck’s pharmacies.

The infractions that are most likely to get your pharmacy fined-and what you can learn from them.

From Pete Kreckel, why chain pharmacists have answers that chains are looking for.

Prescription drone delivery services will be a chain-shipment showdown.

Laboratory analysis now includes ED dietary supplements. 

How chains are evolving-and how pharmacists will fit in.

CVS to emphasize HealthHUB and chains test stand-alone pharmacies.

Savings totaled $293 billion in 2018.

Abbreviated New Drug Applications, state laws, and more.

Analysts now speculating potential next moves.

Site will offer CBD education and product marketing.

Walgreens and a California chain announced closures this week.

Governor Pritzker pushing for lighter pharmacy workloads.

Drug shortages might be decreasing, but their continued existence is urging the pharmacy industry to maintain its vigilance.

Education can help pharmacists feel more comfortable dispensing care.

Job growth may stagnate and retail jobs continue to dwindle. 

What new laws could mean for pharmacies’ role in combatting HIV.

Many cite PBM fees as the primary cause in NCPA survey.

The deal is now official, but the companies have been acting as one for some time.

Patients at-risk for substance abuse more easily identified and managed.

First new treatment of its kind in over 20 years.

Characterized by severe abdominal pain.

The DEA had access to information about where opioids were being sold, but didn’t act on it. Why?

Biosimilars may need more time to devleop in the market.

For granulomatosis with microscopic polyangiitis in children.

Now approved for risk reductions in patients with type 2 diabetes mellitus.